Proteus Digital Health, Otsuka Pharmaceutical sign health deal

REDWOOD CITY, CA & TOKYO – Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. have enetered an exclusive worldwide license and collaboration agreement for the development and commercialization of a new category of medicines. These medicines will be based on Otsuka’s pharmaceutical products and Proteus’ digital health feedback system. Proteus’ novel sensor-based technologies will be incorporated.

Under the agreement, Proteus and Otsuka will collaborate in developing commercial products in two defined therapeutic areas of high unmet medical need. Otsuka has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities.

The Proteus digital health feedback system utilizes wearable and ingestible sensor technologies designed to help improve patients’ health habits. Detailed information, such as when a medication has been taken, is captured and delivered to a secure database, accessible from a variety of platforms such as mobile phones with patient consent. The information is designed to help patients and their caregivers better manage their conditions and to help clinicians provide more effective care.